To address this, researchers tested a new strategy: combining semaglutide (the active ingredient in Ozempic and Wegovy) with an experimental drug called bimagrumab. Bimagrumab is a lab-made antibody ...

Weight-loss jabs have been linked to hundreds of people falling ill with a life-threatening illness and 10 deaths, the UK’s ...

The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

In February, the FDA determined that the semaglutide shortage, spurred on by the appeal of the diabetes treatments' use as a weight-loss drug, had been resolved. But that isn't necessarily the cause ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...

A large study led by researchers at Case Western Reserve University suggests that semaglutide—a drug already popular for ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...